Biomedical researchers studying cellular heterogeneity face a critical decision: selecting an RNA profiling method that aligns with both the biological question and the available tissue sample. Creative Biolabs is drawing attention to three complementary approaches—single-cell RNA sequencing (scRNA-seq), single-nucleus RNA sequencing (snRNA-seq), and single-molecule fluorescence in situ hybridization (smFISH)—that together address different aspects of this challenge. The company's announcement underscores a growing recognition that no single method fits all experimental scenarios, and that early method selection can significantly influence the quality and interpretability of downstream data.
The importance of this development lies in the limitations of conventional bulk RNA analysis, which measures average gene expression across a population of cells and can obscure rare cell types, transient cellular states, and cell-to-cell differences. For studies involving viable, dissociated cells, Creative Biolabs offers a single-cell RNA sequencing service that encompasses experimental planning, cell isolation, library preparation, sequencing, and data analysis. This workflow can help identify distinct cell populations and characterize expression signatures in cancer, immunology, and developmental biology. However, tissue dissociation can introduce biases, as certain cells may be difficult to recover intact and sample handling can alter transcriptional states.
For complex tissues such as brain specimens or samples that resist dissociation, Creative Biolabs provides single-nucleus RNA sequencing. By analyzing isolated nuclei rather than whole cells, this approach can accommodate suitably preserved frozen tissues and reduce some dissociation-related biases. Yet the methods are not directly interchangeable: whole-cell and nuclear RNA profiling capture different transcript populations, and nuclei isolation can introduce method-specific biases. Sample preservation, RNA integrity, and research objectives all influence the information obtained.
Sequencing can suggest that a gene is enriched in a particular cell population, but some follow-up questions require direct visualization. Creative Biolabs' single-molecule FISH analysis service uses fluorescently labeled oligonucleotide probes to detect selected RNA molecules in fixed cells, supporting investigation of transcript abundance and subcellular localization. Unlike transcriptome-wide sequencing, conventional smFISH typically examines preselected RNA targets and requires careful probe design and controls. Its value lies in focused questions—such as whether a transcript is present in particular cells or where it accumulates—rather than replacing broad discovery profiling.
Together, these approaches give researchers a spectrum of options. A project might use scRNA-seq to characterize accessible cells, switch to snRNA-seq when intact-cell recovery is problematic, or apply smFISH to examine the localization of priority transcripts. The implications for the life sciences industry are significant: as research increasingly demands single-cell resolution, matching sample preparation to downstream analysis early can save time and resources while improving data reliability. Creative Biolabs notes that all services are intended for research use only, not for diagnostic or therapeutic purposes.
